MCM
CERE

Moore Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Moore Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$424K – 558
2023
Q4 		$424K Buy
+10,000
New +$287K 0.01% 304

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Moore Capital Management's CERE Position: Q1 2024 in Review

Moore Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 10,000 shares — an estimated $424K sold.

Moore Capital Management first reported a position in CERE in Q4 2023 and held it in 1 quarter. The position peaked at $424K in Q4 2023. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • Moore Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Moore Capital Management sold 10,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $424K.
  • Moore Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Moore Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $424K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Moore Capital Management's 13F filing for Q1 2024, filed 15 May 2024.